Passlick B, Pantel K, Kubuschok B, Angstwurm M, Neher A, Thetter O, Schweiberer L, Izbicki JR: Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer 1996, 32A:141–145.PubMed 26. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S: HLA class I antigen and

transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998, 58:737–742.PubMed 27. Saio M, Teicher M, Campbell G, Feiner H, Delgado Y, Frey AB: Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma. Clin Exp Metastasis 2004, 21:243–249.PubMed 28. Ryschich E, Notzel T, Hinz U, Autschbach F, Ferguson BMN673 J, Simon I, Weitz J, Frohlich B, Klar E, Buchler MW, Schmidt J: Control of T-cell-mediated SN-38 immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005,11(2 Pt 1):498–504.PubMed 29. Sharpe JC, Abel PD, Gilbertson JA, Brawn P, Foster CS: Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human click here prostatic epithelium. Br J Urol 1994, 74:609–616.PubMed 30. Brasanac D, Markovic-Lipkovski J, Hadzi-Djokic J, Muller GA, Muller CA: Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma:

correlation with clinical and histopathological data. Neoplasma 1999, 46:173–178.PubMed 31. Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ: Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 1993, 69:651–659.PubMed 32. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ: Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995, 57:366–375.PubMed 33. Cruz I, Meijer CJ, Walboomers JM, Snijders PJ, Van der Waal I: Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas.

Br J Cancer 1999, 81:881–889.PubMed 34. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel Mirabegron PA: Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 2000, 6:2794–2802.PubMed 35. Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A: Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 2004, 109:393–401.PubMed 36. Lanier LL: Natural killer cells: from no receptors to too many. Immunity 1997, 6:371–378.PubMed 37. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O’Reilly RJ, Dupont B, Vyas YM: Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.